Skip to main content
Caplight Logo









Nuntius Therapeutics

Nuntius Therapeutics

Private
LondonHealthcare & Life Scienceshttps://nuntiustx.com/

Last Round

Seed

Mar 23, 2021

Est. Valuation

$1.79M

Total Funding Raised

$125,000

Company Overview

Nuntius Therapeutics is a biotechnology company that develops mRNA and gene-editing therapies using a proprietary, machine-learning-driven nanocarrier platform for cell-specific delivery.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

nanocarriermRNA therapeuticsgene editingdrug deliverygenetic medicinetargeted therapybiotech platformdrug discoveryin-silico screeningnon-immunogenicprecision medicineAI drug designdelivery vehicleLNP alternativesnext-gen delivery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nuntius Therapeutics Comparables

Compare Nuntius Therapeutics with similar companies based on industry and business-model similarity.

Nuntius Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Code Biotherapeutics
80%
Apertura Gene Therapy
74%
Bristol Myers Squibb
73%

Nuntius Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMar 23, 2021

Key People

Founding team and executive leadership

Benita Nagel

Co-Founder And CEO

Founding Team

Nuntius Therapeutics Investors

Notable investors and investment history

Nuntius Therapeutics investors
InvestorRounds
Backed VCSeed
FoundersX VenturesSeed
Uncommon DenominatorSeed
Asymmetry VenturesSeed
Y CombinatorSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 15, 2026

    Monthly visitors increased 32% MoM.

  • Mar 23, 2021

    $125K round led by Y Combinator

Nuntius Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nuntius Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nuntius Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Employee Range8
Year Founded2021
Last FundingMar 23, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?